Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias
Steven L. Higgins, MD, FACC*,*,
John D. Hummel, MD, FACC ,
Imran K. Niazi, MD, FACC ,
Michael C. Giudici, MD, FACC ,
Seth J. Worley, MD, FACC||,
Leslie A. Saxon, MD, FACC¶,
John P. Boehmer, MD, FACC#,
Michael B. Higginbotham, MD**,
Teresa De Marco, MD, FACC¶,
Elyse Foster, MD, FACC¶ and
Patrick G. Yong, MSEE
* Scripps Memorial Hospital, La Jolla, California, USA
Riverside Methodist Hospital, Columbus, Ohio, USA
St. Luke's Presbyterian Hospital, Milwaukee, Wisconsin, USA
Genesis Medical Center, Davenport, Iowa, USA
|| Lancaster General Hospital, Lancaster, Pennsylvania, USA
¶ University of California San Francisco Medical Center, San Francisco, California, USA
# The Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA
** Duke University School of Medicine, Durham, North Carolina, USA
 Guidant Corporation, St. Paul, Minnesota, USA

View larger version (22K):
[in a new window]
|
Figure 1 Study design for each phase. Phase I (top) was a crossover design (n = 248); Phase II (bottom) was a parallel design (n = 333). CRT = cardiac resynchronization therapy; Rand = randomization time.
|
|

View larger version (15K):
[in a new window]
|
Figure 2 Kaplan-Meier curves for all-cause mortality (left) and all-cause mortality and heart failure (HF) hospitalization (right). CRT = cardiac resynchronization therapy.
|
|
|